Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AS3MT | Q9HBK9 | 2/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15613729 | 0.89 | AS3MT (0.52) | AS3MTNSD2MAOBIKBKEPIM1 | |
| SCHEMBL15472736 | 0.82 | ERBB2 (0.58) | RAB9APIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2645516 | 0.81 | ADORA1 (0.58) | GAARAB9ASMN1; SMN2XDHHSD17B10 | |
| SCHEMBL16979037 | 0.80 | ADORA1 (0.44) | AS3MTNSD2GAARAB9AKDM4E | |
| SCHEMBL7026138 | 0.79 | AS3MT (0.54) | AS3MTNSD2MAOBIKBKEPIM1 | |
| SCHEMBL15472824 | 0.78 | RAB9A (0.53) | MAPTGAARAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL18005919 | 0.77 | MAOB (0.55) | MAOBIKBKEMAPTGAARAB9A | |
| SCHEMBL16979068 | 0.77 | ADORA1 (0.40) | AS3MTNSD2MAPTGAAGHSR | |
| SCHEMBL18006090 | 0.76 | MAOB (0.54) | MAOBIKBKEMAPTGAARAB9A | |
| SCHEMBL13946138 | 0.76 | IP6K1 (0.51) | AS3MTNSD2MAOBPIM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2021-10-12 | — | — | US | disclosed |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2021-10-12 | — | — | US | disclosed |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEONE MEDICINES I GMBH (CH) | 2020-05-14 | — | — | US | disclosed |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEONE MEDICINES I GMBH (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2020-02-25 | — | — | US | disclosed |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2020-02-25 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| CN-102316733-A | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INST MEDICAL W & E HALL | 2012-01-11 | — | — | CN | disclosed |
| EP-2373163-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | AS3MT 4577/4885NSD2 687/4885MAOB 462/4885 |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | AS3MT 3542/4885NSD2 3061/4885MAOB 2170/4885 |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | AS3MT 3542/4885NSD2 3061/4885MAOB 2170/4885 |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | AS3MT 3542/4885NSD2 3061/4885MAOB 2170/4885 |
| US-11142528-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | AS3MT 3542/4885NSD2 3061/4885MAOB 2170/4885 |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | AS3MT 3542/4885NSD2 3061/4885MAOB 2170/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | AS3MT 3542/4885NSD2 3061/4885MAOB 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.